Prostate Cancer Screening With Abbreviated MRI Protocol

NARecruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

May 1, 2022

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2025

Conditions
Prostate Cancer
Interventions
DIAGNOSTIC_TEST

magnetic resonance

biparametric MRI with protocol including anatomical T2 sequence and diffusion-weighted images (DWI), according to the standards

DIAGNOSTIC_TEST

serum PSA examination

testing of prostate-specific antigen (PSA) in serum

PROCEDURE

Biopsy

"Men with a positive MR test are planned for a targeted MRI/US fusion and systematic prostate biopsy.~Men with a positive blood marker (either PSA, PSAD, or PHI) are planned for a systematic 12 core biopsy. Positive test results are PSA ≥ 3, integrated marker PSAD ≥ 0.15, and PHI ≥ 35."

Trial Locations (1)

65653

RECRUITING

Masaryk Memorial Cancer Institute, Brno

All Listed Sponsors
collaborator

Masaryk University

OTHER

lead

Masaryk Memorial Cancer Institute

OTHER